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Abstract: In their article, Morris and Baladandayuthapani clearly evidence the
influence of statisticians in recent methodological advances throughout the bioinfor-
matics pipeline, and advocate for the expansion of this role. The latest acquisition
platforms, such as next generation sequencing (genomics/transcriptomics) and hy-
phenated mass spectrometry (proteomics/metabolomics), output raw datasets in the
order of gigabytes; it is not unusual to acquire a terabyte or more of data per study.
The increasing computational burden this brings is a further impediment against the
use of statistically rigorous methodology in the pre-processing stages of the bioinfor-
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matics pipeline. In this article I describe the mass spectrometry pipeline and use it
as an example to show that beneath this challenge lies a two-fold opportunity: (i)
Biological complexity and dynamic range is still well beyond what is captured by
current processing methodology, hence potential biomarkers and mechanistic insights
are consistently missed; (ii) Statistical science could play a larger role in optimizing
the acquisition process itself. Data rates will continue to increase as routine clinical
omics analysis moves to large-scale facilities with systematic, standardized protocols.
Key inferential gains will be achieved by borrowing strength across the sum total of
all analyzed studies, a task best underpinned by appropriate statistical modeling.
Key words: Computational Statistics; Sparse Signal Processing; Mass Spectrome-
try; Proteomics; Metabolomics
1 Introduction
Largely replacing the use of 2-D gel electrophoresis, mass spectrometry (MS) in-
terfaced to liquid chromatography (LC) or gas chromatography (GC) is now a key
multi-billion dollar industry for profiling the protein and metabolite content of tissues
and bodily fluids. Metabolites (small molecules) are the intermediates of biochemical
reactions. Their levels are determined by the properties and concentration of protein
enzymes, and hence are a consequence of many regulatory processes involving the
genome, transcriptome and proteome. While reflecting the underlying transcriptome
to some degree, proteins are also modulated by many factors such as post-translational
modifications and protein-protein interactions. Disease processes either cause or effect
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perturbations of the proteome and metabolome, hence their study is key to disease
understanding. MS is therefore utilized at all stages of biological science, translational
medicine and drug development to increase confidence in rationale.
Targeted MS approaches are utilized pervasively for drug metabolite identification and
to monitor safety markers in toxicology. More recently, untargeted global profiling of
the proteome and metabolome with MS has gained significant traction for discovery
of disease mechanism and drug targets by generating pre-clinical and clinical evidence
of their relevance to pathophysiology and phenotype, and their effect on disease and
safety implicated biological pathways when modulated. In the systems medicine
paradigm, the omics data (from MS and genomics/transcriptomics approaches such
as next-generation sequencing) feed into knowledge-base guided pathway analysis and
computational biology tools, supporting expert-guided literature review to establish
the evidence base. Complementary to this, and critical to the success of modern drug
development and diagnostics programs, untargeted MS is also key to the characteri-
zation of predictive, prognostic and mechanistic clinical biomarkers that realize early
detection of a disease process or enable patient stratification based on drug safety
or efficacy. The ultimate aim is the generation of specific assays that can accurately
and reproducibly measure the levels of biomarkers in patient populations, compatible
with use in a busy clinical environment. To date, most protein assays are gener-
ally based around antibodies, despite recent high-profile concerns with repeatability
(Baker, 2015), 2015).Targeted MS offers significant advantages and has a clear role
either to validate protein biomarkers in large clinical cohorts prior to costly antibody-
based assay development, or for the clinical assay itself, as is already the case for small
molecule analysis.
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MS of whole proteins is still challenging, hence to reduce spectrum complexity the
dominant bottom-up methodology cuts proteins into smaller peptides prior to anal-
ysis, using an enzyme such as trypsin that cleaves at predictable positions. In untar-
geted proteomics and metabolomics, the biological sample is pre-separated by LC (or
GC for volatile metabolites), to reduce complexity. Each small interval of elution out
of the LC or GC column is ionized before mass analysis to determine the mass-to-
charge ratio (m/z) of each of its constituent molecules. Each abundant biochemical
appears as multiple mass spectral features with different charge states, adducts, losses
or modifications, each with an intensity proportional to its abundance. Quantification
of absolute abundance is non-trivial in untargeted MS as there is no accurate method
to universally predict the scaling factor between a features intensity and its abun-
dance. Nevertheless, since this coefficient is stable for each feature in well-controlled
experimental conditions, comparison of relative intensity across biological samples
can be used to quantify changes in relative abundance. Each feature is also observed
as a series of peaks at increasing m/z due to the presence of natural isotopes such as
13C. The relative intensity of these peaks (the isotope distribution) is characteristic
of the underlying molecular formula and can give a putative identification for that
biochemical, but given that many metabolites and peptides share the same molecular
formula, further mass analysis is necessary to identify definitively. In data-dependent
acquisition (DDA), the most intense features are selected by a second low-resolution
mass spectrometer for collision-induced fragmentation by a noble gas, with the m/z of
these fragment ions captured by a third mass spectrometer. The resultant fragmen-
tation patterns are predictable, enabling the routine identification of peptides by this
method. Metabolite identification may require further rounds of fragmentation to in-
crease specificity, and may include comparison with authentic biochemical standards.
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DDA has been the workhorse approach for years, but limitations include biased and
incomplete coverage due to intensity-dependent selection, and co-selection leading to
chimeric fragmentation spectra that are difficult to interpret. In recent years, Data
Independent Acquisition (DIA) strategies have emerged which mitigate these issues
by using one or multiple broad selection windows that cover the mass range. In this
approach fragmentation data is available for all successfully ionized and fragmented
biochemicals, but due to the wide selection windows used many biochemicals are
fragmented together. Unlike DDA, the fragment elution profiles are available, how-
ever, and so in theory fragments with matching elution profiles can be clustered back
together by the bioinformatics pipeline.
2 Bioinformatics challenges
As stated by Morris and Baladandayuthapani, Driven by the computational chal-
lenges of high dimensionality and out of convenience, many commonly used standard
analysis approaches are reductionistic (not modeling the entire data set), ad hoc
and algorithmic (not model-based), stepwise and piecemeal (not integrating informa-
tion together in a statistically efficient way or propagating uncertainty through to
the final analysis). This succinctly describes the pervasive approach in proteomics
and metabolomics MS. There are a number of commercial (e.g. Nonlinear Dynamics
Progenesis, Waters Coorporation) and academic packages (e.g. MaxQuant (Cox and
Mann, 2008) for proteomics, XCMS (Tautenhahn et al., 2012) for metabolomics) avail-
able. However, their approach is to take a series of deterministic, self-contained steps
(Bessant, 2016) e.g. peak detection; clustering of peaks into quantitative features;
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matching features across samples under chromatographic deformation; identification
by pattern matching of fragments against databases of theoretically or experimentally
derived spectra; grouping of peptides of a protein (protein inference), or adducts of
a metabolite (metabolite inference); modeling associated quantifications to infer pro-
tein quantification; differential analysis across experimental conditions. Raw data is
invariably converted to a symbolic representation at an early stage, so: (1) statistical
evidence is lost from one stage to the next, thus errors propagate and amplify; (2)
once detailed structure inherent in the raw data is gone, it is no longer possible to de-
tect or quantify overlapping spectral signals; (3) since peaks are detected in isolation
with no higher-level knowledge, numerous features are never even detected, despite
informative evidence across the experiment as a whole.
In the beginning, these issues were more or less irrelevant since the mainstays of pro-
teomics MS analysis (life sciences research) and metabolomics (organic chemistry)
predominantly used simplified model systems defined and manipulated within tightly
controlled experimental environments. Bioinformatics methodology for MS, how-
ever, continues to be fundamentally reliant on these characteristics. In biomedical
research, despite stringent control of confounding factors in experimental design, a
step-change in complexity and heterogeneity is evident within typical disease mod-
els and clinical samples. The field has acknowledged this challenge, but has tackled
it mainly by improving the instrumentation. The introduction of the Orbitrap in-
strument (Hu et al., 2005),where ions are trapped electrostatically in orbit around
a central electrode to induce a current capturing the frequency of oscillation of all
ions simultaneously, yielded a step-change in performance due to its high resolution;
in Orbitrap data less signals overlap, therefore more data can be interpreted by the
bioinformatics tools. The resolution of other vendors instrumentation, mainly based
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on time-of-flight analyzers (Chernushevich et al., 2001), where ions are subjected to an
accelerating voltage and drift down a field-free flight tube in a duration quadratically
related to m/z, has now narrowed or eliminated this gap - particularly when consid-
ered together with additional resolving power through extremely fast cycle times or
third-dimension separations using ion mobility. Nevertheless, this comes at a cost;
current-generation instrumentation retail from $0.5 to $1 million. Furthermore, three
significant problems remain: (1) The rate of data output has increasing tremendously
(5-20Gb per dataset is now not uncommon), which continues to discourage software
developers from using the raw data for more than just simple peak detection; (2)
Ionization efficiency has not improved with cycle time, hence less ions are recorded
within each spectrum; nosier peaks are more difficult to extract. (1) The distribu-
tion of biomolecular signals across m/z is markedly non-uniform since the molecules
are largely composed of protons and neutrons that are approximately one atomic
mass unit in mass. Hence signals cluster together and often continue to overlap,
while unfragmented molecular isomers will always overlap in MS. Morris and Bal-
adandayuthapani assert that statisticians understand the profound effect of sampling
design decisions and that Statistical expertise in the experimental design and low-
level processing stages are equally if not more important than end stage-modeling. I
am in agreement but would go further and suggest that statisticians could also have a
strong influence on the design and operation of the instruments themselves. Spectral
acquisition is optimized for visual interpretation, while existing bioinformatics tools
aim to mirror that visual interpretation. There is the opportunity for statistical mod-
elers to work with instrument engineers to optimize based on minimizing inferential
uncertainty based on jointly-constructed generative models of MS formation.
Since few MS bioinformatics tools propagate uncertainty or borrow strength within
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or across steps, inaccuracies and incorrect decisions cascade and amplify downstream.
This contrasts with the development of probabilistic models for next-generation se-
quencing (Glaus et al., 2012; Li and Dewey, 2011), which has moved the field from
differential gene expression towards the more challenging goal of robust compara-
tive analysis of gene isoforms (transcripts). Probabilistic models are used to infer
isoform-level abundances and their differences. However, in MS proteomics the anal-
ysis of protein isoforms (Webb-Robertson et al., 2014), which include protein species
heterogeneity at DNA-level (allelic variations), RNA-level (alternative isoforms) and
protein-level (post translational modifications - PTMs), is still in its infancy: Most
protein inference methodology considers only the most consensus abundance pattern
per protein, which is hoped to be representative (Serang and Kll, 2015). In studies
on eukaryotes of higher complexity (most animals and plants for example), shared
peptides are the norm rather than the exception, and in many cases peptides unique
to a single protein isoform do not exist. This is a significant challenge for protein
assay development by targeted MS, as peptides used for quantification need to be (i)
unique in that type of biological sample, (ii) offer sufficiently sensitive detection on
the MS, and (iii) be recoverable from the biological sample in a highly reliable and
reproducible manner. Current resources for targeted MS curate useful peptide data
regarding specificity of the peptide and its fragments. However, there is currently
a lack of critical data on peptide recovery and quantitative reproducibility which
is required for optimal peptide selection and rapid and robust assay development.
Alongside these developments, in 2014 two teams published high-profile drafts of the
human proteome (Kim et al., 2014; Wilhelm et al., 2014) potentially a gold mine
for translational medicine. While the drafts attain wide protein identification cover-
age, they also underline the statistical challenges facing current methodology, which
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is only just beginning to deal with false-discovery rate issues in studies of this scale
(Serang and Noble, 2012). Moreover, at present the draft proteomes only include
simple quantitative information, of limited utility to clinical biomarker discovery.
In clinical samples there are also a number of confounding factors that are difficult
to avoid and challenging to downstream statistical modeling and Intregromics (Mor-
ris and Baladandayuthapani, section 6.2), such as (i) interaction between multiple
disease processes, (ii) decoupling between disease sites and sampling sites such as
biofluids, and (iii) the aggregation of multiple latent endotypes exhibiting similar
phenotype, such as in asthma. The integration of quantitative outputs from pro-
teomics and metabolomics into rigorous statistical models for pre-clinical and clinical
trial design (e.g. mixed-effects models, survival/frailty models), clinical prediction
models (e.g. logistic regression) and latent endotype models (e.g. factor analysis,
Bayesian networks) is reliant on their appropriate and accurate statistical handling.
Unfortunately, this is exceptionally problematic with current pipelines, since multi-
ple confounding effects are coalesced into single measurements with complex error
distributions, non-linearity and large amounts of outliers and data missing not at
random. There are two main mechanisms for this missingness: (i) Low intensity fea-
tures are much more likely to be censored due to insensitivity in the feature detection
method; (ii) Features can be missed at random, due to a combination of technical
and informatics issues. Unfortunately these effects are mostly ignored, but mixed-
effects methodology has been presented that can compensate for these missingness
mechanisms and optionally impute the missing data (Karpievitch et al., 2009a). Nev-
ertheless, improved upstream processing with uncertainty propagation would be a
much more optimal consideration.
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3 State of play
One side effect of presenting pre-processed feature data for downstream modeling
is that the true generative model of the raw data has become obfuscated. While
it is universally acknowledged by bioinformaticians that next-generation sequencing
generates count data, it is less well understood that the same is true for most MS
instruments nb. Orbitrap and related devices output a signal that aims to be propor-
tional to the underlying ion counts. Studies have shown that the Poisson distribution
is a good fit to mass spectral noise, dwarfing other components, while isotope dis-
tributions exhibit multinomial variation (Du et al., 2008). Nevertheless, MS feature
detection approaches universally assume Gaussian noise. A Poisson model of ion-
counting statistics immediately offers two advantages: Firstly, negative counts are
unattainable. Secondly, it supports the observation that variance appears to drop as
m/z increases, which has led to approaches to estimate variance in each segment of
a spectrum (Wang et al., 2008). However, since peak width tends to increase as m/z
rises, peaks will on average decrease in intensity, assuming average peak volumes re-
main constant. A Poisson explanation would predict this heteroscedastic relationship
between intensity and variance.
We have recently demonstrated a biomarker discovery pipeline that markedly im-
proves sensitivity over state-of-the-art commercial software by operating at the raw
data level throughout, using a pipeline of (i) sparse regression with a Poisson like-
lihood, (ii) image registration to account for chromatogram alignment, and (iii)
Bayesian functional wavelet mixed-effects modeling (Liao et al., 2014). Neverthe-
less, much more needs to be done. Firstly, functional regression does not remove the
requirement for feature detection, since the derived changes need to be assigned to
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the proteins or metabolites they relate to. Moreover, while functional regression can
have a significant effect on feature detection performance simply because the derived
differential features are much less likely to overlap than all features together, feature
extraction approaches must continue to be improved, as cataloging the identity of all
proteins/metabolites in a dataset will always remain an important use case. Given the
scale of the raw data, from a computational viewpoint the use of High Performance
Computing clusters and/or Graphical Processing Units is pertinent. From a statisti-
cal modeling viewpoint the debate is whether Bayesian computational approaches are
necessary or whether point-based methods would be sufficient, given that information
on uncertainty is already duplicated across the dataset by the sets of features relating
to the same protein or metabolite. The efficacy of the later has already been demon-
strated under the prior assumption that the spatial distribution of features is sparse
e.g. The NITPICK method (Renard et al., 2008) utilizes a non-negative extension
of the LASSO to extract whole features from MS data. More recently, an analogous
approach based on mixture modeling has also been proposed (Browne et al., 2010).
Secondly, while we found substantial amounts of significant novel differential expres-
sion on clinical DDA data, the majority of these candidate biomarkers were expressed
at too low a level to be selected for fragmentation. DIA has significant potential to
mitigate this issue, but post-hoc clustering to assign fragments to their unfragmented
parents has only been partially effective; at present identification coverage has not
greatly surpassed DDA (Tsou et al., 2015). Nevertheless, existing methodology does
not consider uncertainty. In metabolomics, the equivalent problem of clustering to-
gether metabolite adducts (metabolite modifications generated during ionization) has
been tackled successfully with a hierarchical Bayesian mixture model (Suvitaival et al.,
2014). In this approach, the chromatographic profiles of each adduct are extracted
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and their pairwise correlation calculated for input into the model.
If you consider solely statistical contributions operating on pre-processed data, there
is a healthy amount of activity in the field. To briefly illustrate a subset, chro-
matogram alignment has been demonstrated using a Bayesian mixture model with
a Dirichlet Process prior (Benjamin et al., 2013), or Hidden Markov Models with
inference provided by either Expectation-Maximization (Listgarten et al., 2007) or
Markov-Chain Monte Carlo (MCMC) (Befekadu et al., 2011). Time-dependent in-
strumental drift and batch effects have been investigated using Surrogate Variable
Analysis (Karpievitch et al., 2009b) and corrected for by a hierarchical Bayesian
model incorporating Gaussian Process priors (Ranjbar et al., 2015). In metabolomics,
Latent Dirichlet Allocation has been utilized as a topic model to extract and cluster
common sub-patterns from fragmentation spectra (Hooft et al., 2016). These com-
mon sub-patterns are indicative of shared molecular substructures that enable some
mechanistic interpretation where a full identification is infeasible. In proteomics,
feature-based mixed-effects modeling is popular, and is used for integrated modeling
of the study design together with relationships between feature-level and protein-level
quantification. Models have been fitted using Restricted Maximum Likelihood (Choi
et al., 2014), and extended to include both M-estimation for robustness to outliers
and empirical Bayes to borrow strength across proteins (Goeminne et al., 2015). A
recent Bayesian MCMC solution includes modelling of individual peptide variance,
down-weighting the influence of unreliable peptides on the result (Freeman et al.,
2015).
One area that could see increased research focus is structured learning incorporating
protein and metabolite pathway information. Both Protein-Set Enrichment Analysis
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(Lavalle-Adam et al., 2014) and Metabolite Pathway Enrichment Analysis (Kankainen
et al., 2011) have been presented, which utilize biological knowledge-base information
in a manner analogous to GSEA (Morris and Baladandayuthapani, Section 6.1). How-
ever, it is vital to consider such approaches using early or intermediate data rather
than end-stage protein/metabolites quantifications, in order to handle the significant
uncertainties inherent in MS data, both in terms of quantifications and, in particular
for metabolomics, identifications (Rogers et al., 2009). Data-driven structure learning
and integromics has seen limited research; a notable contribution is the technique of
Latent Protein Trees, which offers a Bayesian latent factor model that establishes a
binary tree of correlations that could represent the hierarchy of peptides, proteins
and biological pathways (Henao et al., 2013). Its integration with gene expression
data was discussed in (Carin et al., 2012).
4 Conclusion
In this article I have illustrated the landscape of current bioinformatics tools for
MS, and have shown that despite the richness of information contained in modern
MS datasets, much is thrown away at the early stage of the bioinformatics pipeline
before statistical modeling is performed. There are significant opportunities to impact
the field through the development of scalable modeling techniques for pre-processing
MS data, firstly to extract far more of the biological complexity and dynamic range
that remains hidden, and secondly to optimize the acquisition process itself, which
is unnecessarily detailed for some regions of the proteome, whilst lacking for others.
Methods such as these will significantly increase our understanding of underlying
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variations in MS experiments in a clinical setting and provide an enabling pathway
ultimately leading to enhanced sensitivity and robustness of these technologies in
translational and clinical research.
The promise of clinical proteomics and metabolomics has led to the establishment
of several large-scale biomarker discovery facilities worldwide, including the Stoller
Biomarker Discovery Centre (SBDC) for proteomics at The University of Manchester,
and the UK Phenome Centres for metabolic phenotyping at Imperial College London
and the University of Birmingham. The SDBC facility, for example, combines the
latest instrumentation and techniques for robust discovery proteomics, candidate set
validation on thousands of samples, through to targeted MS of individual biomark-
ers for clinical assay development. Crucially, as these centers are underpinned by
standard operating procedures controlling collection, preparation and analysis across
thousands of samples, they will provides us with the unique opportunity to develop
statistical modeling tools that borrow strength over the sum complement of all stud-
ies analyzed, in order to characterize the biological and technical variation key to
biomarker validation and clinical assay development, across the spectrum of health
and disease, with technical bias minimized and comparability maximized.
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